Evidence map›Paper›PMID 36662903›Full record

Trial reportPloS one2023

Effect of acetazolamide on visuomotor performance at high altitude in healthy people 40 years of age or older-RCT.

Aurelia E Reiser, Michael Furian, Mona Lichtblau, Aline Buergin, Simon R Schneider, Paula Appenzeller, Laura Mayer, Lara Muralt, Maamed Mademilov, Ainura Abdyraeva and 8 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03536520 (Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03536520 phase4completednot on this map

Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial

TypeinterventionalSponsorUniversity of ZurichRan2018 to 2018Enrolled59ConditionsAltitude HypoxiaArmsACETAZOLAMIDE oral capsule, Placebo oral capsule
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Effects ofFood science & nutrition · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Aurelia E ReiserDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Michael FurianDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Mona LichtblauDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Aline BuerginDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Simon R SchneiderDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Paula AppenzellerDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Laura MayerDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Lara MuraltDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Maamed MademilovSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Ainura AbdyraevaSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Shoira AidaralievaSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Aibermet MuratbekovaSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Azamat AkylbekovSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Ulan SheralievSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Saltanat ShabykeevaSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Talant M SooronbaevSwiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland/ Bishkek, Kyrgyz Republic.
Silvia UlrichDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.
Konrad E BlochDepartment of Respiratory Medicine, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-2377-7387
University Hospital of Zurich · CHNational Center of Cardiology and Internal Medicine · KG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAltitude travel is increasingly popular also for middle-aged and older tourists and professionals. Due to the sensitivity of the central nervous system to hypoxia, altitude exposure may impair visuomotor performance although this has not been extensively studied. Therefore, we investigated whether a sojourn at moderately high altitude is associated with visuomotor performance impairments in healthy adults, 40y of age or older, and whether this adverse altitude-effect can be prevented by acetazolamide, a drug used to prevent acute mountain sickness.

methodsIn this randomized placebo-controlled parallel-design trial, 59 healthy lowlanders, aged 40-75y, were assigned to acetazolamide (375 mg/day, n = 34) or placebo (n = 25), administered one day before ascent and while staying at high altitude (3100m). Visuomotor performance was assessed at 760m and 3100m after arrival and in the next morning (post-sleep) by a computer-assisted test (Motor-Task-Manager). It quantified deviation of a participant-controlled cursor affected by rotation during target tracking. Primary outcome was the directional error during post-sleep recall of adaptation to rotation estimated by multilevel linear regression modeling. Additionally, adaptation, immediate recall, and correct test execution were evaluated.

resultsCompared to 760m, assessments at 3100m with placebo revealed a mean (95%CI) increase in directional error during adaptation and immediate recall by 1.9° (0.2 to 3.5, p = 0.024) and 1.1° (0.4 to 1.8, p = 0.002), respectively. Post-sleep recall remained unchanged (p = NS), however post-sleep correct test execution was 14% less likely (9 to 19, p<0.001). Acetazolamide improved directional error during post-sleep recall by 5.6° (2.6 to 8.6, p<0.001) and post-sleep probability of correct test execution by 36% (30 to 42, p<0.001) compared to placebo.

conclusionIn healthy individuals, 40y of age or older, altitude exposure impaired adaptation to and immediate recall and correct execution of a visuomotor task. Preventive acetazolamide treatment improved visuomotor performance after one night at altitude and increased the probability of correct test execution compared to placebo. CLINICALTRIALS.GOV IDENTIFIER: ClinicalTrials.gov NCT03536520.

Indexed as

AcetazolamideAltitude SicknessAdultAgedAltitudeDouble-Blind MethodHumansHypoxiaMiddle AgedSleepAcetazolamide

Identifiers

PMID36662903
PMCPMC9858039
OpenAlexW4317602523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.